InVivoSIM anti-human BCMA (Belantamab Biosimilar)

About InVivoSIM anti-human BCMA (Belantamab Biosimilar)

This non-therapeutic biosimilar antibody uses the same variable regions as the therapeutic antibody, Belantamab, making it ideal for research use. Belantamab is a humanized IgG1 monoclonal antibody that reacts with B-cell maturation antigen (BCMA), also known as CD269 or tumor necrosis factor receptor superfamily member 17 (TNFRSF17). BCMA is a single-pass type III membrane glycoprotein, and it is selectively expressed by mature or differentiated plasma B-cells in normal lymphoid tissues (e.g., bone marrow, spleen, lymph nodes, and tonsils). BCMA is not expressed on naive B cells, T cells, monocytes/macrophages, neutrophils, and other normal tissues. BCMA is expressed uniformly and in high abundance in multiple myeloma tissues, and its low-to-moderate levels of expression are reported in several other hematologic malignancies also (e.g., chronic lymphocytic leukemia, acute B-lymphoblastic leukemia, and non-Hodgkin/Hodgkin lymphomas). BCMA acts as a receptor for two distinct agonist ligands: B cell-activating factor [BAFF (also known as TNFSF13B or BLyS)] and a proliferation-inducing ligand (APRIL, also called TNFSF13). In comparison to BAFF/Blys, BCMA binds APRIL/TNFSF13 with higher affinity. BCMA plays a critical role in promoting B-cell survival and the regulation of humoral immunity. BCMA is also involved in the activation of NF-kappa-B and JNK-3 signaling pathways. In multiple myeloma, BCMA expression is directly related to the growth/proliferation of cancer cells, and serum levels of soluble BCMA (sBCMA) are suggested as a potential biomarker in multiple myeloma. In several experimental studies, an antibody-drug conjugate (ADC) consisting of belantamab conjugated to mafodotin has been shown to induce antibody-dependent cellular cytotoxicity (ADCC) and apoptosis in cancer cells.